Grace Therapeutics, INC. (GRCE) — SEC Filings

Overview

Grace Therapeutics, INC. (GRCE) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q/A filed on Nov 17, 2025: Grace Therapeutics, Inc. (GRCE) filed a Form 10-Q/A on November 17, 2025, solely to amend the number of outstanding common shares on its cover page for the quarter ended September 30, 2025. The corrected number of outstanding shares of common stock as of November 13, 2025, is 15,474,026. This amendm

Sentiment Summary

Across 35 filings, the sentiment breakdown is: 1 bearish, 34 neutral. The dominant filing sentiment for Grace Therapeutics, INC. is neutral.

Filing Type Overview

Grace Therapeutics, INC. (GRCE) has filed 2 10-Q/A, 18 8-K, 5 10-Q, 1 DEF 14A, 2 10-K, 2 SC 13G/A, 2 DEFA14A, 3 SC 13G with the SEC between Jan 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (35)

• Grace Therapeutics Amends 10-Q for Share Count Correction — 10-Q/A · Nov 17, 2025 Risk: low
  Grace Therapeutics, Inc. (GRCE) filed a Form 10-Q/A on November 17, 2025, solely to amend the number of outstanding common shares on its cover page for the quar
• Grace Therapeutics Files 8-K — 8-K · Nov 13, 2025 Risk: low
  Grace Therapeutics, Inc. filed an 8-K on November 13, 2025, reporting on its results of operations, financial condition, and other events. The filing also inclu
• Grace Therapeutics Files 8-K — 8-K · Oct 23, 2025 Risk: low
  Grace Therapeutics, Inc. filed an 8-K on October 23, 2025, reporting other events and financial statements. The company, formerly known as Acasti Pharma Inc. un
• Grace Therapeutics Files 8-K — 8-K · Sep 18, 2025 Risk: low
  Grace Therapeutics, Inc. filed an 8-K on September 18, 2025, reporting on "Other Events" and "Financial Statements and Exhibits." The company, formerly known as
• Grace Therapeutics Files 8-K on Shareholder Matters — 8-K · Sep 12, 2025 Risk: low
  Grace Therapeutics, Inc. filed an 8-K on September 12, 2025, to report on matters submitted to a vote of its security holders. The company, formerly known as Ac
• Grace Therapeutics Files 8-K — 8-K · Aug 27, 2025 Risk: low
  Grace Therapeutics, Inc. filed an 8-K on August 27, 2025, reporting other events and financial statements. The company, formerly known as Acasti Pharma Inc., is
• Grace Therapeutics' Net Loss Widens to $5.2M Amid R&D Push — 10-Q · Aug 12, 2025 Risk: high
  Grace Therapeutics, Inc. (GRCE) reported no revenue for the quarter ended June 30, 2025, consistent with its status as a clinical-stage pharmaceutical company.
• Grace Therapeutics Sets Virtual Annual Meeting for Sept. 12 — DEF 14A · Jul 28, 2025 Risk: low
  Grace Therapeutics, Inc. (GRCE) has filed a definitive proxy statement (DEF 14A) for its 2025 Annual Meeting of Stockholders, scheduled virtually for September
• Grace Therapeutics Files 8-K — 8-K · Jun 25, 2025 Risk: low
  Grace Therapeutics, Inc. filed an 8-K on June 25, 2025, reporting on other events and financial statements. The company, formerly known as Acasti Pharma Inc. un
• Grace Therapeutics Maintains Nasdaq Listing, Compliance Status — 10-K · Jun 23, 2025 Risk: medium
  Grace Therapeutics, Inc. (GRCE) reported its 10-K for the fiscal year ended March 31, 2025, indicating its status as a non-accelerated filer and a smaller repor
• Grace Therapeutics Files 8-K — 8-K · Apr 9, 2025 Risk: low
  Grace Therapeutics, Inc. filed an 8-K on April 9, 2025, reporting other events and financial statements. The company, formerly known as Acasti Pharma Inc. until
• Grace Therapeutics Files 8-K — 8-K · Mar 3, 2025 Risk: low
  Grace Therapeutics, Inc. filed an 8-K on March 3, 2025, reporting on Other Events and Financial Statements and Exhibits. The company, formerly known as Acasti P
• Grace Therapeutics Files 10-Q/A for Q3 2024 — 10-Q/A · Feb 19, 2025 Risk: low
  Grace Therapeutics, Inc. filed an amendment (10-Q/A) on February 19, 2025, for the quarterly period ended December 31, 2024. The company, formerly known as Acas
• Grace Therapeutics Files Q3 2024 10-Q — 10-Q · Feb 13, 2025 Risk: low
  Grace Therapeutics, Inc. filed its 10-Q report for the quarterly period ended December 31, 2024. The company, formerly known as Acasti Pharma Inc., is incorpora
• Grace Therapeutics Files 8-K on Agreements and Equity Sales — 8-K · Feb 10, 2025 Risk: medium
  Grace Therapeutics, Inc. filed an 8-K on February 10, 2025, reporting on a material definitive agreement, unregistered sales of equity securities, and other eve
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Grace Therapeutics Files 10-Q for Q2 2024 — 10-Q · Nov 13, 2024 Risk: low
  Grace Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Acasti Pharma Inc., is incorporated in Delaware
• Grace Therapeutics Changes Fiscal Year End — 8-K · Oct 28, 2024 Risk: low
  Grace Therapeutics, Inc. filed an 8-K on October 28, 2024, reporting a change in its fiscal year end to March 31. The company, formerly known as Acasti Pharma I
• Acasti Pharma Files 8-K — 8-K · Oct 25, 2024 Risk: low
  Acasti Pharma Inc. filed an 8-K on October 25, 2024, to report other events and financial statements. The filing does not contain specific details about the nat
• Acasti Pharma Enters Material Agreement, Modifies Security Holder Rights — 8-K · Oct 7, 2024 Risk: medium
  Acasti Pharma Inc. announced on October 1, 2024, that it entered into a material definitive agreement. The company also made material modifications to the right
• Acasti Pharma Files 8-K: Director Changes & Shareholder Votes — 8-K · Sep 30, 2024 Risk: medium
  Acasti Pharma Inc. filed an 8-K on September 30, 2024, reporting on the departure of directors, election of new directors, and compensatory arrangements. The fi
• Acasti Pharma Files 8-K — 8-K · Sep 25, 2024 Risk: low
  Acasti Pharma Inc. filed an 8-K on September 25, 2024, reporting other events and financial statements. The company, incorporated in Quebec with principal execu
• Acasti Pharma Inc. Proxy Statement: Your Vote Matters! — DEFA14A · Sep 6, 2024 Risk: low
  Acasti Pharma Inc. filed a Definitive Additional Materials (DEFA14A) on September 6, 2024, related to its Annual and Special Meeting of Shareholders. The filing
• Acasti Pharma Relocates Principal Offices — 8-K · Aug 16, 2024 Risk: low
  Acasti Pharma Inc. announced on August 12, 2024, a change in its principal executive offices to 103 Carnegie Center, Suite 300, Princeton, New Jersey, 08540. Th
• Acasti Pharma 10-Q: Financials & Warrant Adjustments — 10-Q · Aug 9, 2024 Risk: medium
  Acasti Pharma Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial position and operations, including details on commo
• Acasti Pharma Files Proxy Materials — DEFA14A · Aug 7, 2024 Risk: low
  Acasti Pharma Inc. filed a Definitive Additional Materials (DEFA14A) on August 7, 2024. This filing is related to proxy materials and does not require a filing
• SC 13G Filing — SC 13G · Jul 10, 2024
• Acasti Pharma Files 8-K with Office and Contact Info — 8-K · Jun 27, 2024 Risk: low
  Acasti Pharma Inc. filed an 8-K on June 27, 2024, reporting other events and financial statements. The filing details the company's principal executive offices
• Acasti Pharma Files 2024 10-K — 10-K · Jun 21, 2024 Risk: medium
  Acasti Pharma Inc. filed its 10-K for the fiscal year ending March 31, 2024, reporting on its financial condition and business operations. The company, incorpor
• SC 13G Filing — SC 13G · Apr 9, 2024
• Acasti Pharma Files 8-K for Regulatory Disclosure — 8-K · Apr 1, 2024 Risk: low
  Acasti Pharma Inc. filed an 8-K on April 1, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specif
• SC 13G Filing — SC 13G · Feb 13, 2024
• Acasti Pharma Inc. Files 10-Q for Period Ending December 31, 2023 — 10-Q · Feb 12, 2024 Risk: low
  Acasti Pharma Inc. (GRCE) filed a Quarterly Report (10-Q) with the SEC on February 12, 2024. Acasti Pharma Inc. filed a 10-Q report for the period ending Decemb
• Acasti Pharma 8-K: Executive Comp & Leadership Changes — 8-K · Jan 8, 2024
  Acasti Pharma Inc. filed an 8-K on January 5, 2024, to report changes in its executive compensation arrangements and potentially the departure or election of di

Risk Profile

Risk Assessment: Of GRCE's 29 recent filings, 1 were flagged as high-risk, 6 as medium-risk, and 22 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Grace Therapeutics, INC.'s most recent 10-Q filing (Aug 12, 2025):

• Revenue: $0
• Net Income: -$5.2M
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: N/A
• Operating Margin: N/A
• Total Assets: N/A
• Total Debt: N/A

Key Executives

• Prashant Kohli
• Robert DelAversano
• Amresh Kumar
• Carrie D'Andrea
• R. Loch Macdonald

Industry Context

Grace Therapeutics, Inc. operates within the biotechnology and pharmaceutical sector, a highly competitive and innovation-driven industry. Companies in this space focus on research and development of novel therapeutics, often facing long development cycles, significant regulatory hurdles, and the need for substantial capital investment. The industry is characterized by rapid scientific advancements, patent cliffs, and strategic partnerships or acquisitions to advance drug pipelines.

Top Tags

8-K (7) · corporate-filing (5) · 10-Q (5) · financials (4) · filing (4) · Biotechnology (3) · SEC Filing (3) · regulatory-filing (3) · corporate-actions (3) · Pharmaceuticals (3)

Key Numbers

• Outstanding shares of common stock: 15,474,026 — Corrected number as of November 13, 2025, on the cover page
• Par value per share: $0.0001 — Common stock par value
• Filing date of 10-Q/A: November 17, 2025 — Date the amendment was filed
• Quarterly period ended: September 30, 2025 — Period for which the original 10-Q was filed
• Original 10-Q filing date: November 13, 2025 — Date the unamended 10-Q was filed
• SEC File Number: 001-35776 — Identifies the company's filing with the SEC.
• IRS Employer Identification No.: 98-1359336 — Company's tax identification number.
• Central Index Key: 0001444192 — Unique identifier for the company in the SEC EDGAR system.
• Revenue: $0 — Grace Therapeutics reported no revenue for the quarter ended June 30, 2025, consistent with its clinical-stage status.
• Net Loss: $5.2M — The net loss for the quarter ended June 30, 2025, increased by 8.3% from $4.8 million in the prior year, indicating higher operational costs.
• Increase in Net Loss: 8.3% — The net loss increased from $4.8 million in Q2 2024 to $5.2 million in Q2 2025, reflecting increased R&D expenses.
• Annual Meeting Date: September 12, 2025 — Date stockholders will vote on key proposals
• Director Nominees: 5 — Number of directors to be elected for a one-year term
• Fiscal Year End: March 31, 2026 — Period for which KPMG LLP is appointed as auditor
• Meeting Time: 8:30 a.m. ET — Specific time the virtual annual meeting will commence

Forward-Looking Statements

• {"claim":"Acasti Pharma will continue to focus on cost control to extend its cash runway.","entity":"Acasti Pharma Inc.","targetDate":"2024-09-30","confidence":"high"}
• {"claim":"The company may seek additional financing if R&D expenses increase for later-stage clinical trials.","entity":"Acasti Pharma Inc.","targetDate":"2025-03-31","confidence":"medium"}

Related Companies

ACST

Frequently Asked Questions